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Partnership Among Dermatology, the Society 
for Investigative Dermatology, and Industry: 
Suggestions for Change
Several months ago, Braham Shroot described in the Journal of Investigative Dermatology (JID) (2007) his view of rela-
tionships between the Society for Investigative 
Dermatology (SID) and industry based on 20 
years’ experience as an active member of the SID 
and the pharmaceutical industry. He described 
deficiencies in understanding between the 
SID and industry, but he also described a new 
dialogue and concrete initiatives intended 
to improve that relationship, including cre-
ation of the annual course “SID Basics of Skin: 
Pharmaceutics & Pharmacology.”
At the invitation of the JID’s Editor-in-Chief, 
I write to extend this discussion by addressing: 
(i) how dermatology as a medical discipline and 
its attractiveness for research and development 
investment are perceived by the industry and (ii) 
how investigative dermatologists in academia 
and the SID perceive and interact with members 
of the pharmaceutical industry. In my conclu-
sion, I raise for discussion several suggestions 
intended to foster mutual understanding and 
partnership.
I have worked in pharmaceutical research at 
the Sandoz Research Institute and its successor, 
the Novartis Institutes for Biomedical Research 
in Vienna, since 1974. Most of my research has 
been devoted to the discovery and development 
of novel approaches and therapies for skin dis-
ease. This work began in the late 1970s with the 
discovery of a novel class of antimycotics, the 
allylamine derivatives, culminating in the dis-
covery of terbinafine, which was synthesized 
in my laboratory in 1980 (Petranyi et al., 1984; 
Stuetz, 1987, 1993, 2007). Then, in the late 
1980s, we initiated a project resulting in the dis-
covery of the topical calcineurin inhibitors as a 
new class of compounds for treating inflamma-
tory skin diseases, ultimately leading to the mar-
keting of pimecrolimus (Meingassner and Stuetz, 
1992; Stuetz et al., 2006). Additional projects 
have been created since that time, and I hope 
that some of these will also prove to be useful in 
the short- to mid-term future.
I became a member of the SID in 1989, and 
since 2005 I have served as a member of its 
Board of Directors. I consider this an honor, not 
only because I am an industry scientist but also 
because I am a European who lives outside of 
the United States.
One of the major issues I have witnessed 
over the past two decades is an underestima-
tion of the importance and market potential of 
dermatology-related therapies compared with 
that of other organ-specific diseases. Possible 
reasons for this include the following:
1. Skin diseases are common but rarely life-
threatening. Thus, the medical necessity 
of investing in new treatments is not as 
obvious to the public as, for example, the 
need to invest in cardiovascular disease or 
cancer. To counter this perception, it seems 
to me that dermatologic diseases must be 
deﬁned and described in new ways. In fact, 
a landmark study describing the “burden of 
skin disease” on society, including its direct 
costs, was published recently (Bickers et al., 
2006). On the other hand, this publication 
includes data collected only in the United 
States, not from a global perspective, and it 
seems to have not yet been widely utilized.
2. Dermatologic research is not recognized 
as a major contributor to progress in 
biomedical research and is thus not 
perceived as a source of new and innovative 
medical therapies. Many drugs used by 
dermatologists were developed ﬁrst for 
indications other than those related to skin.
3. Very few drugs used to treat skin 
diseases have had blockbuster sales. The 
dermatology market is fragmented  
and dominated by inexpensive and 
relatively old medicines that have outlived 
patent protection.
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4. Several pharmaceutical companies have left skin disease, 
most likely due to a lack of innovation and relatively low 
sales.
5. Today only a few of the global pharmaceutical 
companies (still) have signiﬁcant R&D activities 
speciﬁcally dedicated to skin disease.
In view of these assertions, it seems difficult within “big 
pharma” to assess the medical need and the market poten-
tial of skin disease and, consequently, to recruit support for 
dermatology-related activities or to foster the understanding 
that dermatology plays an important role in medical science 
and therapy.
Through my many interactions with dermatologists and 
academic scientists who work in skin research, it has become 
evident that there is often a negative attitude toward, and a 
low level or even lack of knowledge and understanding about, 
research in industry. Working on industry-sponsored projects 
may even be considered a disadvantage for those who pur-
sue academic careers, and evidence of collaboration may 
not be utilized in preparing a curriculum vitae for fear of an 
academic’s being perceived as “contaminated.” In contrast, I 
have enjoyed several excellent collaborations with scientists 
in academic centers, resulting in the sort of peer-reviewed 
publications that one finds in the JID (Rappersberger et al., 
1996, 2002; Hoetzenecker et al., 2004, 2005; Krummen et 
al., 2006). Thus, I know from personal experience that sci-
ence-driven collaboration can create fruitful partnerships 
for both parties, in academia as well as in industry. This phe-
nomenon was featured in the Novartis-sponsored symposium 
“Partnership Between Academia and Industry to Progress 
Understanding and Therapy of Skin Diseases” held at the 
34th European Society for Dermatologic Research (ESDR) 
Annual Meeting in Vienna in 2004.
The SID, together with the ESDR and the Japanese Society 
for Investigative Dermatology (JSID), are the most important 
scientific representatives of dermatology as a science-based 
medical discipline, with significant records of promoting 
research. On the other hand, research in dermatology is not 
limited to academic centers; industrial research contributes 
in substantial ways to new therapies. In my opinion, the 
industrial contributions to this research enterprise are insuf-
ficiently represented and insufficiently valued at SID events. 
One piece of evidence for this is that within the past three 
SID meetings, presenters in 11 industry-sponsored symposia 
were drawn exclusively from academic centers, and thera-
peutic products resulting from sponsoring industries were 
hardly described, if mentioned at all. I understand fully that 
the SID does not want its annual meeting to be distorted 
by market-driven symposia or industry-dominated booths. 
However, if the SID wants industry to be interested in skin 
research and to continue or strengthen sponsorships, indus-
try should be given a fair chance to be visible and valued 
adequately at SID-sponsored events.
Another aspect for consideration is that the attractiveness of 
the Annual Meeting to industry researchers may be increased 
by highlighting or making more transparent the many presen-
tations that are a source or basis for new therapeutic approach-
es. The meeting abstracts, which are published in the JID, are 
great for “experts,” allowing them to find out what is new and 
interesting in their specific subdisciplines, but abstracts alone 
can be enormously confusing to beginners and non-experts 
who want to learn about dermatology in general and to learn 
about novel therapeutic approaches. It seems that only a few 
clinical studies about new therapies are presented at the SID 
annual meeting, and few are published in the JID.
What can be done to address these concerns? The sugges-
tions below are intended to promote further discussion:
• Expand, complement, and then feature the concept of 
“burden of skin disease.” The recent document (Bickers 
et al., 2006) was a good start, but this effort should be 
updated and expanded, including a global dermatology 
perspective, e.g., with the help of the ESDR and the JSID. 
In its expanded form, this report should be published in 
a broad and global way to reach scientists, the medical 
community, patients, and industry (managers), and it 
should become visible to the population at large.
• Prove and then communicate the proof that progress 
in skin research contributes to progress in biomedical 
research in general and thus that cutaneous biology 
plays an important role in medical science and general 
medical therapy.
• Utilize the many excellent presentations at annual 
SID meetings to increase awareness of the innovative 
potential of dermatology research for non-experts. This 
could be supported by publishing reviews by experts 
who summarize SID oral and poster presentations 
in “New Trends in Immunology (Pharmacology, 
Keratinocyte Biology, etc.)” after each SID meeting in 
subsequent JID issues.
• Invite distinguished industry scientists to give keynote 
lectures on research (and development) concerning new 
therapies for skin disease at SID meetings. A summary 
on this may be published in JID, together with the expert 
summaries mentioned above.
• Provide awards, not only to academic but also to 
industry scientists, for breakthrough discoveries.
• Encourage at least one of the presenters in each industry-
sponsored symposium to be from industry—of course, 
with the clear task of focusing on science.
• Create a dedicated slot or symposium at the SID annual 
meeting for the presentation of clinical research and 
studies of new therapies and encourage publication of 
science-driven clinical studies in the JID.
• Increase global activities of the SID in collaboration 
with the ESDR and the JSID beyond the International 
Investigative Dermatology (IID) meeting every 5 years in 
order to strengthen the global aspects, awareness, and 
recognition of dermatology.
The suggestions listed above are intended to be starting 
points for discussion, as well as to stimulate further sugges-
tions and contributions by readers with the aim of supporting 
dermatology research by improved understanding and part-
nership among academia, industry, and the SID. Ultimately, 
patients would benefit from this improved relationship.
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